PL3662894T3 - Nanocząstki zawierające takrolimus - Google Patents

Nanocząstki zawierające takrolimus

Info

Publication number
PL3662894T3
PL3662894T3 PL19213120T PL19213120T PL3662894T3 PL 3662894 T3 PL3662894 T3 PL 3662894T3 PL 19213120 T PL19213120 T PL 19213120T PL 19213120 T PL19213120 T PL 19213120T PL 3662894 T3 PL3662894 T3 PL 3662894T3
Authority
PL
Poland
Prior art keywords
takrolimus
nanoparticles containing
nanoparticles
containing takrolimus
Prior art date
Application number
PL19213120T
Other languages
English (en)
Inventor
Wolfgang Beier
Elke Horstkotte
Original Assignee
Leon-Nanodrugs Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leon-Nanodrugs Gmbh filed Critical Leon-Nanodrugs Gmbh
Publication of PL3662894T3 publication Critical patent/PL3662894T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL19213120T 2018-12-04 2019-12-03 Nanocząstki zawierające takrolimus PL3662894T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102018130848 2018-12-04
EP19213120.9A EP3662894B1 (en) 2018-12-04 2019-12-03 Nanoparticles comprising tacrolimus

Publications (1)

Publication Number Publication Date
PL3662894T3 true PL3662894T3 (pl) 2022-01-10

Family

ID=68766584

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19213120T PL3662894T3 (pl) 2018-12-04 2019-12-03 Nanocząstki zawierające takrolimus
PL19816295.0T PL3846783T3 (pl) 2018-12-04 2019-12-04 Nanocząstki zawierające takrolimus

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL19816295.0T PL3846783T3 (pl) 2018-12-04 2019-12-04 Nanocząstki zawierające takrolimus

Country Status (18)

Country Link
US (2) US11311479B2 (pl)
EP (2) EP3662894B1 (pl)
JP (1) JP7641220B2 (pl)
KR (1) KR20210100142A (pl)
CN (2) CN113242732A (pl)
AU (1) AU2019392718B2 (pl)
CA (1) CA3063417C (pl)
DK (2) DK3662894T3 (pl)
ES (2) ES2894112T3 (pl)
FI (1) FI3846783T3 (pl)
HR (1) HRP20240072T1 (pl)
HU (2) HUE056067T2 (pl)
IL (1) IL283458A (pl)
PL (2) PL3662894T3 (pl)
PT (1) PT3846783T (pl)
SG (1) SG11202105778PA (pl)
SI (2) SI3662894T1 (pl)
WO (1) WO2020115140A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3202761A1 (en) 2020-11-25 2022-06-02 Nanocopoeia, Llc Amorphous cabozantinib particles and uses thereof
CA3216600A1 (en) * 2021-05-05 2022-11-10 Christian DUBIELLA Methods for producing nanoparticle dispersions
CN113425716A (zh) * 2021-05-27 2021-09-24 南京诺亚药业有限公司 一种他克莫司药物组合物及其制备方法
EP4104816A1 (en) * 2021-06-14 2022-12-21 Nucleus Medical GmbH Non-nanoparticulate applications forms of macrolides
AU2023232910A1 (en) * 2022-03-11 2024-09-12 Lts Lohmann Therapie-Systeme Ag Transmucosal therapeutic system containing a macrolide immunosuppressant
US20250319019A1 (en) * 2022-09-10 2025-10-16 Smita PATTANAIK Buccomucoadhesive patch-based drug delivery system for tacrolimus
KR20250136925A (ko) * 2023-02-06 2025-09-16 뉴클리어스 메디칼 게엠베하 면역 질환 또는 장애를 예방 또는 치료하는 방법에 사용하기 위한 마크로라이드
EP4410287A1 (en) * 2023-02-06 2024-08-07 Nucleus Medical GmbH A macrolide for use in a method of preventing or treating an immunological disease or disorder
EP4501320A1 (en) * 2023-08-02 2025-02-05 IQ medical GmbH A method of preparing an aqueous dispersion of nanoparticles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06001776A (es) 2003-08-15 2007-09-07 Qlt Usa Inc Sistema de suministro de farmaco transmucosal biocorrosivo, adhesivo.
JP2008524239A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミティド ナノ粒子のタクロリムス製剤
AU2008288105A1 (en) * 2007-03-29 2009-02-19 Panacea Biotec Limited. Modified dosage forms of tacrolimus
WO2012026896A1 (en) * 2010-08-25 2012-03-01 Les Laboratoires Medis Sa Surface modified micronized tacrolimus crystalline particles and pharmaceutical compositions thereof
CN105142619A (zh) * 2013-02-21 2015-12-09 麻省理工学院 药剂的靶向颊内递送
JP2018510859A (ja) 2015-03-17 2018-04-19 レオン−ナノドラッグズ ゲーエムベーハー 安定化されたボロン酸化合物を含むナノ粒子
DE102016101232A1 (de) 2016-01-25 2017-07-27 Instillo Gmbh Verfahren zum Herstellen von Emulsionen

Also Published As

Publication number Publication date
FI3846783T3 (fi) 2024-01-15
US20220079872A1 (en) 2022-03-17
EP3662894B1 (en) 2021-07-28
HRP20240072T1 (hr) 2024-05-10
EP3662894A1 (en) 2020-06-10
CN120324378A (zh) 2025-07-18
SG11202105778PA (en) 2021-06-29
KR20210100142A (ko) 2021-08-13
WO2020115140A1 (en) 2020-06-11
EP3846783B1 (en) 2023-10-18
CA3063417A1 (en) 2020-06-04
IL283458A (en) 2021-07-29
ES2969096T3 (es) 2024-05-16
ES2894112T3 (es) 2022-02-11
SI3846783T1 (sl) 2024-03-29
US20200170934A1 (en) 2020-06-04
CA3063417C (en) 2023-01-03
PL3846783T3 (pl) 2024-04-02
EP3846783B8 (en) 2023-11-22
US11904048B2 (en) 2024-02-20
HUE056067T2 (hu) 2022-01-28
HUE065588T2 (hu) 2024-06-28
PT3846783T (pt) 2024-01-19
CN113242732A (zh) 2021-08-10
AU2019392718B2 (en) 2025-07-24
JP2022513697A (ja) 2022-02-09
DK3846783T3 (da) 2024-01-15
JP7641220B2 (ja) 2025-03-06
DK3662894T3 (da) 2021-09-20
AU2019392718A1 (en) 2021-06-10
US11311479B2 (en) 2022-04-26
EP3846783A1 (en) 2021-07-14
SI3662894T1 (sl) 2021-11-30

Similar Documents

Publication Publication Date Title
DK3731771T3 (da) V462033dk00
EP3589248A4 (en) CRYOTHERAPIES
DE202018003363U8 (de) Handgelenkssphygmomanometer
EP3634404C0 (en) PYRAZOLE-BASED MAGL INHIBITORS
IL283458A (en) Nanoparticles comprising tacrolimus
EP3697802A4 (en) TRITERPENIC SAPONIN ANALOGUES
EP3588580A4 (en) SCHOTTKY MOS TRENCH DIODE
DK3351526T3 (da) Diisopentylterephthalat
EP3721165C0 (en) MILITARY CHARGE
EP3654852A4 (en) TOURNIQUET
DK3568655T3 (da) Rekuperator
DK3571580T5 (da) Load-logical-and-shift-guarded-instruktion
DK3612237T3 (da) Genterapi
EP3611402A4 (en) SERVO CYLINDER
EP3615471A4 (en) PLASMA PHOTOELECTRONIC IMMUNE SENSOR
EP3558864A4 (en) NANOPARTICLES
EP3669219C0 (en) NETWORK SCALE
EP3684343C0 (en) IMPROVED SUPERPARTICLES
EP3714787A4 (en) BIOSENSOR
DK3576686T3 (da) Brokbind
DK3568506T3 (da) Offeranode
FI11704U1 (fi) Liittopuujärjestely
EP3623755A4 (en) RULER
EP3683885B1 (en) LEAD-ACID BATTERY
FI11529U1 (fi) Ontelolaatan kannake